5-Amino-1MQ: Benefits, Side Effects, and Uses

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule research compound that blocks an enzyme called nicotinamide N-methyltransferase, or NNMT. In preclinical studies, mostly in mice and rats, this inhibition has produced striking effects on body fat, blood sugar regulation, and muscle function in aging animals. Despite growing interest from longevity and fitness communities, no human clinical trial results for 5-Amino-1MQ have been published, which means its benefits, side effects, and practical uses in people remain genuinely unknown.

What NNMT Does and Why Blocking It Matters

NNMT sits at a metabolic crossroads. The enzyme breaks down nicotinamide, a form of vitamin B3, into a product called 1-methylnicotinamide. In doing so, it pulls nicotinamide away from the pathway that produces NAD+, a molecule cells rely on for energy production, DNA repair, and dozens of other functions. At the same time, NNMT uses up a methyl donor called SAM that the body needs for gene regulation and other methylation reactions. In short, when NNMT is highly active, it drains two important cellular resources at once.

NNMT tends to be overexpressed in white fat tissue, and its activity rises alongside obesity and insulin resistance. In insulin-resistant people, researchers have found a clear inverse relationship: the higher the NNMT expression in fat tissue and the higher the plasma concentration of its product, the worse the insulin sensitivity.¹ That correlation helped make NNMT a target for drug development, and 5-Amino-1MQ emerged as one of the most promising inhibitors.

What makes 5-Amino-1MQ stand out among NNMT inhibitors is its selectivity. In laboratory testing, the compound crossed cell membranes easily through both passive and active transport, yet it did not interfere with related methyltransferases or enzymes in the NAD+ salvage pathway.² That selectivity matters because a drug that accidentally knocks out neighboring enzymes could cause unpredictable problems.

Fat Loss and Metabolic Improvement in Animals

The most consistent finding across preclinical studies is that 5-Amino-1MQ reduces body fat and improves metabolic markers in obese mice. When researchers fed mice a high-fat diet and then treated them with the compound, they saw dose-dependent reductions in body weight and fat mass alongside improved glucose tolerance, better insulin sensitivity, and lower fasting insulin levels.³ “Dose-dependent” is worth flagging here: the effects got stronger as the dose went up, which is a good sign that the compound is genuinely driving the changes rather than being a bystander.

A broader review of NNMT inhibition research, including both genetic knockdown experiments and small-molecule inhibitors, reinforces the pattern. Blocking NNMT in animal models consistently increased energy expenditure, reduced white fat mass, and normalized blood sugar regulation.⁴ The fact that both genetic and pharmacological approaches produce similar outcomes strengthens the case that NNMT itself is the relevant target, not some off-target effect of the drug.

The mechanism behind the fat loss appears to involve multiple pathways. By freeing up nicotinamide that would otherwise be consumed by NNMT, the inhibitor allows more NAD+ to be synthesized, which supports mitochondrial energy production. Meanwhile, preserving SAM keeps methyl groups available for gene-regulatory reactions that can influence how fat cells behave. The net effect, at least in rodents, is that the body burns more energy and stores less fat even without changes in food intake.

Muscle Strength and Aging

Age-related muscle decline is a different problem than obesity, but NNMT inhibition appears to affect both. A 2024 study tested 5-Amino-1MQ in aged mice, with some animals also put through a progressive weighted-resistance exercise program. The results were unexpectedly strong: sedentary aged mice treated with the compound developed roughly 40% greater grip strength than untreated sedentary controls. Aged mice that exercised but received no treatment gained about 20% in grip strength. And when the compound was combined with exercise, grip strength jumped by about 60% over sedentary controls.⁵

The additive nature of that result is the part that caught researchers’ attention. NNMT inhibition and exercise did not merely overlap; they stacked. A treated mouse that also exercised was meaningfully stronger than one that only received the compound or only exercised. That suggests the compound and physical activity are working through at least partially distinct pathways to improve muscle function.

Interestingly, the compound also reduced intramyocellular lipid content, which is the fat stored inside muscle fibers. Accumulation of this intramuscular fat is associated with poor muscle quality in aging and with insulin resistance. Clearing it out could explain some of the functional improvement, as muscles with less internal fat tend to contract more efficiently.

Muscle Fiber Growth Requires the Combination

A subtlety in the same study deserves its own attention because it matters for anyone wondering whether 5-Amino-1MQ alone can build muscle. When researchers measured the cross-sectional area of individual muscle fibers in the gastrocnemius (the large calf muscle), they found that neither the compound alone nor exercise alone produced a statistically meaningful increase. Only the combination of NNMT inhibition and progressive resistance exercise led to fiber growth, with pooled fiber area at least 25% larger than in all other groups.⁵

The largest gains came from Type IIb fibers, which are the fast-twitch fibers that make up the bulk of the gastrocnemius. This is relevant because fast-twitch fibers are the ones that atrophy most dramatically with age, and they are the fibers responsible for explosive strength and power. But the takeaway is clear: in this animal model, the compound appeared to amplify the muscle-building stimulus of exercise rather than replace it. If you are imagining a future where you take a pill instead of going to the gym, this study does not support that fantasy.

Kidney Disease and Cellular Senescence

Beyond fat metabolism and muscle, NNMT has turned up as a player in kidney fibrosis and the kind of cellular aging known as senescence. A 2025 paper in Cell Reports showed that NNMT is linked to tubular senescence and epithelial-to-mesenchymal transition in early chronic kidney disease. In that context, inhibiting NNMT acted as a senotherapeutic strategy, meaning it helped mitigate the buildup of damaged, non-dividing cells that drive scarring and loss of kidney function.⁶

This is early-stage work, but it points to a broader principle: NNMT is not just a metabolic enzyme. It sits at a junction of cellular processes that matter for tissue repair and aging. If inhibiting it can delay the accumulation of senescent cells in the kidney, researchers want to know whether similar effects occur in other organs. The answer is not yet clear, but it helps explain why 5-Amino-1MQ has attracted interest from the longevity research community and not just the obesity field.

How the Body Absorbs and Eliminates 5-Amino-1MQ

Pharmacokinetic data exists for rats, and it paints a reasonably encouraging picture for oral dosing in that species. After oral administration, 5-Amino-1MQ reached a peak plasma concentration of about 2,250 ng/mL, with an elimination half-life of roughly seven hours. Oral bioavailability was calculated at about 38%, meaning a bit more than a third of the swallowed dose reached systemic circulation.⁷ For context, many drugs considered to have “good” oral bioavailability fall in the 30-70% range, so the compound crosses that threshold in rats.

One complication: oral bioavailability in mice is substantially worse, which is why many mouse studies administer the compound by subcutaneous injection rather than oral gavage. This species difference is a reminder that pharmacokinetics can vary dramatically between animals, and what works well in a rat’s gut may not translate directly to a human’s. No published pharmacokinetic data in humans exists, so how well people absorb orally dosed 5-Amino-1MQ remains an open question. The capsules sold by peptide vendors and compounding pharmacies assume oral absorption is adequate, but that assumption has not been validated clinically.

Side Effects and Safety

This is where honest writing about 5-Amino-1MQ gets uncomfortable, because there is very little to report. The animal studies described above generally note that the compound was well tolerated at the doses used, but “well tolerated in a mouse study” is a low bar. Mice do not report headaches, nausea, or mood changes. Published toxicology studies specifically designed to evaluate the safety profile of 5-Amino-1MQ in any species are not available in the peer-reviewed literature.

The selectivity data offers some indirect reassurance. Because the compound does not inhibit related SAM-dependent methyltransferases or enzymes in the NAD+ salvage pathway, the risk of unintended disruption to neighboring biochemical processes is theoretically lower than it would be for a less selective inhibitor.² But selectivity in a cell-based assay and safety in a living human are different things. Plenty of highly selective compounds have caused unexpected toxicity in clinical trials.

Anecdotal reports from people who have self-experimented with 5-Amino-1MQ, found mainly in online longevity and biohacking forums, mention occasional gastrointestinal discomfort and mild headaches. These reports are impossible to verify, may reflect impure products, and carry all the usual limitations of uncontrolled self-experimentation. They should not be mistaken for a safety profile.

There are also theoretical concerns. NNMT plays roles beyond fat metabolism, including in the liver, brain, and immune system. Chronically suppressing an enzyme that participates in methylation reactions and NAD+ regulation across multiple tissues could have consequences that only emerge over months or years. Long-term safety data simply does not exist.

Why None of This Has Reached Human Trials

Given how strong some of the animal data looks, you might wonder why 5-Amino-1MQ has not already entered formal human clinical trials. Part of the answer is practical: developing a drug through the regulatory pipeline costs hundreds of millions of dollars, and NNMT inhibition as a therapeutic strategy is still relatively young. A 2026 review in Trends in Pharmacological Sciences described ongoing progress toward clinical application of small-molecule NNMT inhibitors, framing the field as moving toward but not yet at the point of human testing.⁸

Another part of the answer is scientific. The metabolic effects observed in diet-induced obese mice are dramatic, but mice on a high-fat laboratory diet are a specific model that does not perfectly recapitulate human obesity. The muscle findings in aged mice are compelling, but grip strength in a mouse measured by how hard it holds onto a bar is not identical to functional strength in a 70-year-old human. These models are good enough to justify further research, but the gap between rodent physiology and human physiology is wide enough that the effect sizes could shrink, disappear, or even reverse once the compound is tested in people.

Meanwhile, the compound is already available through research chemical suppliers and some compounding pharmacies, marketed for “research purposes only” but clearly purchased by individuals for personal use. This creates an odd situation: thousands of people may be taking a substance for which the entire evidence base consists of rodent studies and cell culture experiments. That does not mean it is dangerous, but it does mean that anyone taking it is, in effect, running an uncontrolled experiment on themselves.

What Buyers Are Actually Getting

If you search for 5-Amino-1MQ online, you will find it sold as capsules, usually in doses ranging from 50 to 150 mg, by compounding pharmacies and research peptide vendors. The quality and purity of these products vary. Unlike FDA-approved drugs, compounded preparations are not subject to the same manufacturing standards, and third-party testing is inconsistent across vendors. Some sellers provide certificates of analysis; many do not.

The dosing that people use is essentially extrapolated from the animal literature, scaled by body weight, and adjusted by guesswork. The rat pharmacokinetic study that found decent oral bioavailability used a specific formulation and administration method. Whether a commercially sold capsule delivers comparable absorption is anyone’s guess. The species difference in oral bioavailability between rats and mice is a cautionary example: what the gut does with a compound depends heavily on the species, the formulation, and the individual.

People generally take 5-Amino-1MQ as part of a broader fat-loss or longevity regimen, often stacking it with other supplements or peptides. The interaction potential of the compound with other substances has not been studied in any systematic way. If you are taking medications for diabetes, blood pressure, or other metabolic conditions, the lack of interaction data is especially relevant because NNMT inhibition directly affects some of the same metabolic pathways these drugs target.

NNMT in the Broader NAD+ Landscape

5-Amino-1MQ belongs to a broader wave of interest in boosting NAD+ levels for health and longevity. Other approaches include supplementing with NAD+ precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), which aim to increase the supply side. NNMT inhibition takes a different angle: instead of adding more raw material, it prevents the body from wasting the nicotinamide it already has. In theory, these approaches could be complementary. An NNMT inhibitor keeps more nicotinamide in the pipeline, while an NR or NMN supplement increases total precursor availability.

Whether combining them produces better outcomes than either alone has not been tested in a controlled study. The idea is biochemically plausible, and some self-experimenters report doing exactly this, but plausibility and evidence are not the same thing. The field of NAD+ biology is moving fast, with dozens of active research programs, and it is entirely possible that within a few years there will be clinical data to guide these decisions. For now, the honest answer is that nobody knows the optimal strategy for raising NAD+ in humans, or even whether doing so produces the benefits that animal studies suggest.

The Human Evidence That Does Exist for NNMT

While no clinical trial of 5-Amino-1MQ has been published, there is human data on NNMT itself that supports the biological rationale. The study that measured NNMT expression in human fat tissue found a strong inverse correlation between NNMT activity and insulin sensitivity, with higher NNMT expression consistently tracking with worse metabolic health.¹ That is a correlation, not proof that inhibiting the enzyme will fix the problem, but it does confirm that the target is relevant in humans and not just a peculiarity of rodent metabolism.

NNMT expression has also been studied in human cancers, liver disease, and neurological conditions, though 5-Amino-1MQ specifically has not been tested in those contexts. The enzyme appears to be upregulated in several tumor types, which has sparked interest in NNMT inhibitors as potential cancer therapeutics. Whether 5-Amino-1MQ or a more optimized relative will eventually be tested in oncology remains to be seen. For the time being, the compound’s story is one of compelling animal data, a sound biological rationale, and an almost complete absence of the human evidence needed to confirm whether any of it translates to real-world benefit or risk for people.